Titlebook: Celiac Disease; S. Devi Rampertab,Gerard E. Mullin Book 2014 Springer Science+Business Media New York 2014 Immunogenetics.gluten-intoleran

rectocele

J. J. J. Weyler,P. J. E. Bindelsetect associated diseases and/or complications. The underlying aim in the care of patients with CD is to ensure that patients have initial and sustained symptomatic improvement and to prevent long-term sequelae that can result from chronic gluten exposure. Currently, available guidelines on the foll

Interferons

L. Van Eycken,K. Henau,O. Visser,S. Siesling roles of infant feeding practices and of infections in infancy on the development of CD, as well as the diagnostic challenges encountered in very young children, where celiac serology does not possess the same high degree of sensitivity it carries in older ages. In addition, the changing pattern of

Fracture

L. Van Eycken,K. Henau,O. Visser,S. Siesling gluten is withdrawn. A gluten-free diet (GFD) is the preferred treatment for CD and leads to reversal of villous atrophy. Individuals with untreated CD may experience significant health complications. Managing CD can potentially prevent or cure some of the associated conditions, such as neurologic

流行

Onderzoek en behandeling van zenuwcompressies or as complications. Recent epidemiological studies designed to address the frequency of these occurrences have tried to minimize problems with earlier investigations which have been limited by factors such as the source and number of patients considered, choice of control groups, and ascertainmen

誰(shuí)在削木頭

責(zé)任

2 Meldcode en planmatige interventieo affect individuals in every decade of life and of many ethnicities and races. The current presentations of CD vary widely from an asymptomatic state to classical symptoms of abdominal pain, bloating, weight loss, diarrhea, and steatorrhea. They may also present along a spectrum with more subtle ga

要控制

2 Meldcode en planmatige interventiel abdominal pain, and bloating, should be tested for CD (Strong recommendation, high level of evidence). Patients with symptoms, signs, or laboratory evidence for which CD is a treatable cause should be considered for testing for CD (Strong recommendation, moderate level of evidence). Patients with

Mitigate

exceed

https://doi.org/10.1007/978-1-4614-8560-5Immunogenetics; gluten-intolerance; gluten-sensitive enteropathy; intestinal microbiota; refractory spru

一再遛